Biotricity glyph and upwards arrow signifying growth

Biotricity to discuss sales expansion, recent financing, and wearable medical device portfolio expansion at H.C. Wainwright Conference

Company’s momentum continuing with sales growth, recent Nasdaq listing and successful equity raise

SEPTEMBER 08, 2021 | BY BIOTRICITY

REDWOOD CITY, Calif., Sep 08, 2021 (ACCESSWIRE)Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today reported its CEO Waqaas Al-Siddiq is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be available on-demand starting at 7:00 a.m. ET on Monday, September 13, 2021 (details provided below).

Dr. Al-Siddiq will discuss the Company’s continuing sales growth of its FDA-approved Bioflux® mobile cardiac telemetry (MCT) device which, as the Company previously announced, drove its FY22-1Q revenue up 290% YOY and approximately 49% sequentially. He will also discuss sales expansion and the company’s planned product portfolio that the Company believes will increase the current total addressable market (TAM) while growing revenues. As previously announced, Biotricity recently completed a $15 million equity raise and listed on the Nasdaq Capital Market.

The presentation will be available to registered attendees from Monday, September 13 to Wednesday, September 15. To access the presentation, investors may register for the conference here. During the conference, the management team will also be available for virtual one-on-one meetings with registered attendees.

A live webcast of the conference call can be accessed by clicking on the following link: Webcast Audio will stream through your selected device. A full replay of the presentation will be available at the same link shortly after the conclusion of the live presentation and will be available for 90 days.

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Media contacts

Bospar
prforbiotricity@bospar.com

Investor relations:

Biotricity Investor Relations
Investors@biotricity.com
1.800.951.3348

Mark Forney
MKR Group, Inc.
12198 Ventura Blvd., Suite 200
Los Angeles, CA 91604
mark@mkrir.com

Gary Zwetchkenbaum
Plum Tree Consulting LLC
Phone : 718.224.3123
Cell : 516.455.7662